Developments Tiziana Life Sciences submits IND for oral Foralumab Tiziana Life Sciences (NASDAQ:TLSA, AIM:TILS) submitted an IND to the FDA for its enteric-coated capsules of Foralumab, an anti-CD3 monoclonal antibody. Foralumab, believed to induce an anti-inflammatory response by... March 20, 2019